Anixa Biosciences Director Acquires $30,400 of Stock as Company Advances Cancer Programs
Anixa Biosciences director Arnold M. Baskies purchased 10,000 shares of common stock on January 28, 2026, for $3.04 per share, bringing his direct holdings to 135,000 shares. The transaction coincides with recent clinical and intellectual property milestones for the company, even as the stock has pulled back in the past week and trades above a repo…